SCHEMBL13890897

SCHEMBL13890897

COc1ccc(C)c(Nc2ccc(F)cc2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.55
ERBB3 P21860 1/20 0.55
MAPT P10636 2/20 0.54
HTT P42858 1/20 0.54
GAA P10253 2/20 0.53
AKR1C3 P42330 7/20 0.49
AKR1C2 P52895 7/20 0.49
ACP1 P24666 1/20 0.47
KDM4E B2RXH2 1/20 0.47
NPC1 O15118 1/20 0.47
THRB P10828 1/20 0.47
MAPK1 P28482 1/20 0.47
RECQL P46063 1/20 0.47
RAB9A P51151 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
MAOA P21397 1/20 0.46
MAOB P27338 1/20 0.46
LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14850475 0.83 AKR1C3 (0.62) MAPTGAAAKR1C3AKR1C2ACP1
SCHEMBL8686451 0.81 AKR1C3 (0.61) EGFRERBB3MAPTHTTGAA
SCHEMBL23886689 0.80 EGFR (0.51) EGFRERBB3MAPTGAAAKR1C3
SCHEMBL3634234 0.79 GAA (0.55) MAPTGAAAKR1C3AKR1C2KDM4E
SCHEMBL866356 0.78 MAPT (0.77) EGFRERBB3MAPTHTTGAA
SCHEMBL4215631 0.77 AKR1C3 (0.65) EGFRERBB3MAPTAKR1C3AKR1C2
SCHEMBL14392040 0.77 AKR1C3 (0.83) MAPTAKR1C3AKR1C2LMNAPOLB
SCHEMBL2214114 0.76 MAPT (0.58) EGFRERBB3MAPTHTTGAA
SCHEMBL13890891 0.76 CYP3A4 (0.49) EGFRMAPTHTTGAANPC1
SCHEMBL13890980 0.76 MAPT (0.41) EGFRMAPTHTTNPC1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP11, MMP3 EGFR 925/4885ERBB3 1025/4885MAPT 4791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.